Baidu
map

Front Oncol:低剂量白蛋白紫杉醇联合PD-1抑制剂(替雷利珠单抗)治疗老年晚期非小细胞肺癌(NSCLC)患者的疗效

2022-03-24 yd2015 网络

研究表明,低剂量白蛋白紫杉醇联合替雷利珠单抗治疗老年晚期NSCLC患者有效且耐受性可,包括EGFR/ALK变异患者。

近期,来自南京医科大学团队开展了一项II期临床研究,主要是评估老年晚期非小细胞肺癌(NSCLC)患者使用低剂量白蛋白紫杉醇联合PD-1抑制剂(替雷利珠单抗)治疗的疗效和安全性。相关结果发表在Frontiers in Oncology杂志上。

该II期临床研究,纳入≥65岁的转移性NSCLC,既往接受≧1线化疗或靶向治疗后进展,EGFR或ALK阳性患者接受≧1线相应TKI治疗后进展也可纳入。主要终点为无进展生存期和安全性/耐受性。次要终点包括客观缓解率和总生存率。

2019年5月-2020年8月纳入的29例患者中,21例(72.4%)为腺癌,17例(58.6%)PS=2, 8例(27.6%)伴有无症状的脑转移,13例(44.8%)伴有EGFR/ALK阳性。18例(62.1%)可知PD-L1表达水平的患者中,8例PD-L1表达水平<1%;7例患者PD-L1水平为1%-10%,和3例患者>10%。

总体队列患者中位无进展生存期(PFS)为9.5个月(95% CI, 5.8-13.2个月)。腺癌患者的中位PFS为10.9个月(95% CI, 8.6-13.2个月),而鳞状细胞癌患者的中位PFS为3.2个月(95% CI, 0-10.4个月)(风险比[HR], 0.63;95%CI,0.24- 1.62;P = 0.33)。EGFR/ALK野生型非鳞状NSCLC患者的中位PFS(11.9个月;95% CI, 9.3-14.5个月)明显长于EGFR/ALK变异患者(7.0个月;95%CI 3.5-10.5个月)(HR,0.56;95%CI,0.33-0.97;P = 0.032)。

中位OS为16.5个月(95% CI, 10.8-22.3个月)。在亚组分析中,EGFR/ALK野生型腺癌患者的中位OS尚未达到。

10例患者达到部分缓解,ORR为34.5%。DCR为86.2%。腺癌患者的ORR为38.1% (95% CI, 18.1%-61.6%),而鳞状细胞癌患者为25.0% (95% CI, 3.2%-65.1%;P = 0.419)。在非鳞状NSCLC患者中,EGFR/ALK野生型患者的ORR为50.0% (95% CI, 15.7%- 84.3%),而EGFR/ALK变异型患者的ORR为30.8% (95% CI, 9.1%-61.4%) (P = 0.336)。

中位DOR为 9.8个月(95% CI, 5.4 14.3个月)。 18名患者(62.1%)肿瘤大小较基线下降(中位变化-18%)。

17例(58.6%)患者发生至少1种治疗相关不良事件,3例(10.3%)患者发生3级不良事件。没有4级TRAE。最常见的不良事件为疲劳(20.7%)、发热(17.2%)、肝功能异常(17.2%)和皮疹(17.2%)。只有1例患者因为验证TRAE停止治疗。

综上,研究表明,低剂量白蛋白紫杉醇联合替雷利珠单抗治疗老年晚期NSCLC患者有效且耐受性可,包括EGFR/ALK变异患者。

 

原始出处:

Zhu W, Geng Q, Peng H, Jin Z, Li D, Pu X, Wang G and Jiang H (2022) Effificacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer. Front. Oncol. 12:802467. doi: 10.3389/fonc.2022.802467

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-10-25 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-09-07 SHIRLEY L99999

    六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-04-25 minlingfeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-05-26 Y_ANGEL

    希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-03-25 珙桐
  9. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2060101, encodeId=080f206010167, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Jan 17 16:28:44 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 25 06:28:44 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247792, encodeId=6c40124e79298, content=六周期 效果不错。请问 白蛋白结合型紫杉醇 最多多少周期。谢谢 三周一个疗程、 D1 注射用紫杉醇(白蛋白结合型)100mg*4 特瑞普利 80mg*3=240mg 每三周注射一次, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df845460272, createdName=SHIRLEY L99999, createdTime=Wed Sep 07 22:58:06 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 25 20:28:44 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222674, encodeId=485012226e4d6, content=希望替雷利珠单抗(百泽安)联合紫杉醇和卡铂注射液化疗药物治疗NSCLC临床试验取得更前沿的治疗效果!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe623229726, createdName=Y_ANGEL, createdTime=Thu May 26 21:47:05 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206490, encodeId=ef4b1206490e7, content=<a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60362, encryptionId=e555603625e, topicName=替雷利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sun Mar 27 22:57:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278965, encodeId=f67012e896580, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304716, encodeId=09f81304e162a, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480628, encodeId=cfdb1480628be, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Mar 25 04:28:44 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205529, encodeId=cd6b1205529b3, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c545311787, createdName=1488bd11m81(暂无昵称), createdTime=Thu Mar 24 11:35:38 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-03-24 1488bd11m81(暂无昵称)

    支持!

    0

相关资讯

魏强教授:替雷利珠单抗获批晚期尿路上皮癌治疗适应证

2020年4月9日,百济神州自主研发的PD-1单抗替雷利珠单抗(百泽安?)正式获得国家药品监督管理局(NMPA)批准,用于既往接受过治疗的局部晚期或转移性尿路上皮癌患者。至此,替雷利珠单抗成为首个在国

叶定伟教授:替雷利珠单抗横空出世,开启国内晚期尿路上皮癌治疗新篇章

2020年4月9日,百济神州自主研发的PD-1单抗替雷利珠单抗(百泽安?)正式获得国家药品监督管理局(NMPA)批准,用于既往接受过治疗的局部晚期或转移性尿路上皮癌患者。至此,替雷利珠单抗成为首个在国

未来可期!国产PD1抑制剂助力中国晚期NSCLC二线新选择

替雷利珠单抗和信迪利单抗二线治疗明显改善晚期NSCLC患者的OS和PFS,可作为二线治疗的新选择。

杨勇教授:替雷利珠单抗在尿路上皮癌一线免疫联合治疗展示曙光

尿路上皮癌是起源于尿路上皮的一种多源性的恶性肿瘤,包括肾盂癌、输尿管癌、膀胱癌以及尿道癌,是最常见的泌尿系统肿瘤之一。尿路上皮癌患者面临确诊晚、易复发、治疗手段有限等困境。对于局部晚期或转移性尿路上皮

Baidu
map
Baidu
map
Baidu
map